Related Experiment Video
Updated: Jul 29, 2025
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.3K
Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
Jonathan A Bernstein1, Ana Giménez-Arnau2, Marcus Maurer3,4
1Division of Rheumatology, Bernstein Allergy Group and Clinical Research Center, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Journal of Clinical Medicine
|May 27, 2023
Summary
Achieving complete response in chronic spontaneous urticaria (CSU) significantly improves health-related quality of life (HRQoL), including dermatology life quality index (DLQI) and work productivity. Minimal disease activity still shows impairments compared to complete response.
Area of Science:
- Dermatology
- Clinical Trials
- Health Outcomes Research
Background:
- Chronic spontaneous urticaria (CSU) significantly impacts patients' health-related quality of life (HRQoL).
- Understanding the relationship between urticaria activity and HRQoL is crucial for effective treatment strategies.
Purpose of the Study:
- To investigate the association between urticaria activity and HRQoL in patients with CSU.
- To evaluate the impact of treatment response on patient-reported outcomes.
Main Methods:
- Pooled patient data from a Phase 2b clinical trial (NCT02477332) of ligelizumab (N = 382).
- Utilized daily patient diaries to assess urticaria activity (UAS7), sleep and activity interference (SIS7, AIS7), dermatology life quality index (DLQI), and work productivity (WPAI-CU).
- Analyzed patient-reported outcomes based on weekly urticaria activity score (UAS7) bands.
Main Results:
- Over 50% of patients had a baseline DLQI > 10, indicating significant baseline HRQoL impairment.
- Complete response (UAS7 = 0) strongly correlated with no impact on DLQI, SIS7, AIS7, and OWI.
- Complete response (UAS7 = 0) showed significantly better outcomes (91.1% DLQI 0-1, 99.7% SIS7/AIS7 0, 85.3% OWI 0) compared to minimal activity (UAS7 = 1-6).
Conclusions:
- Complete control of urticaria activity is associated with substantial improvements in HRQoL, including dermatology-specific quality of life and work productivity.
- Even minimal urticaria activity (UAS7 = 1-6) is linked to significant impairments in HRQoL compared to complete response.
- Achieving complete response in CSU treatment is vital for restoring patients' overall well-being and daily functioning.
Related Concept Videos
01:30Hypersensitivities
812
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
812
01:26Peptic Ulcer Disease IV: Management
118
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
118
02:06Allergic Reactions
27.9K
Overview
27.9K
01:27Allergic Drug Reactions
901
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
901
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
361
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
361
01:19Antiasthma Drugs: Leukotriene Modifiers
379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
379